Evaluation of carrier added and no carrier added [90]Y-EDTMP as bone seeking therapeutic radiopharmaceutical
Pakistan Journal of Pharmaceutical Sciences. 2014; 27 (4): 813-818
Dans Anglais
| IMEMR
| ID: emr-152587
ABSTRACT
The optimum conditions to label ethylenediaminetetramethylene phosphonate [EDTMP] compound with [90]y as a potential candidate for bone metastases therapy were investigated. Yttrium-90 is a pure beta-emitter and can be obtained by 89y [n,gamma] [90]y nuclear reaction in a reactor or from an in-house generator system [[90]sr[rightwards arrow][90]y]. The preparation of [90]y-EDTMPis described using [90]y, which was obtained from neutron irradiation of y2o3 as well as from a laboratory scale organic resin-based [90]sr[rightwards arrow][90]y generator. Because of the radiolabeling yield of [90]y-EDTMP on ligand/metal molar ratio, incubation time and ph was evaluated. Under optimum parameters, the radiolabeling yields of [90]y-EDTMPwere <95% for no-carrier-added as well as carrier-added [90]y. The biodistribution of no-carrier-added and carrier-added [90]yEDTMPcomplexes in rats was identical. The results indicate that [90]y [carrier-added]-edtmp is also an effective bone pain palliation agent because of its rapid blood clearance, greater uptake in bones and little absorption in soft tissues
Recherche sur Google
Indice:
Méditerranée orientale
langue:
Anglais
Texte intégral:
Pak. J. Pharm. Sci.
Année:
2014
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS